Pembrolizumab with favezelimab or vibostolimab for patients with High-Risk (HR) bacillus Calmette-Guerin (BCG)-unresponsive Non-Muscle-Invasive Bladder Cancer (NMIBC): Phase 2 KEYNOTE-057 cohort C

被引：0
|
作者：
Necchi, A. [1 ,2 ]
Shore, N. D. [3 ]
Gupta, S. [4 ]
Kulkarni, G. [5 ]
Dave, H. [6 ]
Kapadia, E. [6 ]
Zhao, Q. [6 ]
Kamat, A. [7 ]
机构：
[1] Univ Vita Salute San Raffaele, IRCCS San Raffaele Hosp, Milan, Italy
[2] Sci Inst, Dept Med Oncol, Milan, Italy
[3] Carolina Urol Res Ctr, Dept Urol, Myrtle Beach, SC USA
[4] Cleveland Clin, Taussig Canc Ctr, Dept Hematol & Med Oncol, Cleveland, OH 44106 USA
[5] Univ Toronto, Univ Hlth Network, Dept Surg Oncol, Princess Margaret Canc Ctr, Toronto, ON, Canada
[6] Merck & Co Inc, Clin Res, Rahway, NJ 07065 USA
[7] Univ Texas MD Anderson Canc Ctr, Dept Urol Oncol, Houston, TX 77030 USA
来源：
EUROPEAN UROLOGY | 2023年 / 83卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
A0522
引用
收藏
页码：S748 / S748
页数：1
相关论文
共 50 条
  • [1] Phase 2 KEYNOTE-057 cohort C: Coformulations of pembrolizumab (Pembro) and favezelimab or vibostolimab for patients with Bacillus Calmette-Guerin (BCG)-unresponsive High-Risk (HR) Non-Muscle-Invasive Bladder Cancer (NMIBC)
    Gupta, S.
    Kulkarni, G.
    Necchi, A.
    Shore, N. D.
    Dave, H.
    Kapadia, E.
    Zhao, Q.
    Kamat, A.
    [J]. EUROPEAN UROLOGY, 2024, 85 : S433 - S433
  • [2] Pembrolizumab with favezelimab or vibostolimab for patients with bacillus Calmette-Guérin (BCG)-unresponsive high-risk (HR) non-muscle-invasive bladder cancer (NMIBC): Phase 2 KEYNOTE-057 cohort C.
    Kulkarni, Girish S.
    Gupta, Shilpa
    Necchi, Andrea
    Shore, Neal D.
    Dave, Hema Kishore
    Kapadia, Ekta
    Zhao, Qing
    Kamat, Ashish M.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : TPS719 - TPS719
  • [3] Phase 2 KEYNOTE-057 cohort C: Pembrolizumab (pembro) with vibostolimab or favezelimab for patients (pts) with high-risk (HR) bacillus Calmette-Gu ′erin (BCG)-unresponsive non-muscle-invasive bladder cancer (NMIBC).
    Shore, Neal D.
    Gupta, Shilpa
    Kulkarni, Girish S.
    Necchi, Andrea
    Dave, Hema Kishore
    Kapadia, Ekta
    Zhao, Qing
    Kamat, Ashish M.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [4] Pembrolizumab in patients with Bacillus Calmette Guerin (BCG)-unresponsive, high-risk non-muscle-invasive bladder cancer (NMIBC): Phase 2 KEYNOTE-057 study
    de Wit, R.
    Kamat, A. M.
    Bellmunt, J.
    Choueiri, T. K.
    Nam, K.
    De Santis, M.
    Dreicer, R.
    Hahn, N. M.
    Perini, R.
    Siefker-Radtke, A. O.
    Sonpavde, G.
    Witjes, J. A.
    Keefe, S.
    Bajorin, D.
    [J]. ANNALS OF ONCOLOGY, 2016, 27
  • [5] Pembrolizumab for high-risk (HR) non-muscle invasive bladder cancer (NMIBC) unresponsive to bacillus Calmette-Guerin (BCG): Phase II KEYNOTE-057 trial
    de Wit, R.
    Kulkarni, G. S.
    Uchio, E.
    Singer, E. A.
    Krieger, L.
    Grivas, P.
    Bajorin, D.
    Seo, H. K.
    Mourey, L.
    Kamat, A.
    Nishiyama, H.
    Kapadia, E.
    Nam, K.
    Frenkl, T.
    Balar, A.
    [J]. ANNALS OF ONCOLOGY, 2018, 29 : 304 - 304
  • [6] KEYNOTE-057: Phase 2 study of pembrolizumab for patients (pts) with Bacillus Calmette Guerin (BCG)unresponsive, high-risk non-muscle-invasive bladder cancer (NMIBC)
    Kamat, Ashish M.
    Bellmunt, Joaquim
    Choueiri, Toni K.
    Nam, Kijoeng
    De Santis, Maria
    Dreicer, Robert
    Hahn, Noah M.
    Perini, Rodolfo F.
    Siefker-Radtke, Arlene O.
    Sonpavde, Guru
    De Wit, Ronald
    Witjes, Alfred
    Keefe, Stephen Michael
    Bajorin, Dean F.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [7] Updated Interim Analysis from Keynote-057: Pembrolizumab Monotherapy for Patients with High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG)
    Krieger, Laurence
    de Wit, Ronald
    Kulkarni, Girish S.
    Uchio, Edward M.
    Boormans, Joost L.
    Roumiguie, Mathieu
    Singer, Eric A.
    Bajorin, Dean F.
    Kamat, Ashish M.
    Grivas, Petros
    Seo, Ho Kyung
    Nishiyama, Hiroyuki
    Konety, Badrinath R.
    Nam, Kijoeng
    Kapadia, Ekta
    Frenkl, Tara L.
    Balar, Arjun Vasant
    [J]. ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2019, 15 : 52 - 53
  • [8] Pembrolizumab for the treatment of patients with high-risk (HR) non-muscle-invasive bladder cancer (NMIBC) unresponsive to Bacillus Calmette-Guerin: Extended follow-up of KEYNOTE-057 cohort A.
    Balar, Arjun Vasant
    Kamat, Ashish M.
    Kulkarni, Girish S.
    Uchio, Edward M.
    Boormans, Joost L.
    Roumiguie, Mathieu
    Krieger, Laurence Eliot Miles
    Singer, Eric A.
    Bajorin, Dean F.
    Grivas, Petros
    Seo, Ho Kyung
    Nishiyama, Hiroyuki
    Konety, Badrinath R.
    Nam, Kijoeng
    Zambon, Joao Paulo
    Kapadia, Ekta
    De Wit, Ronald
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
  • [9] PHASE 2 KEYNOTE-057 STUDY: PEMBROLIZUMAB FOR PATIENTS WITH HIGH-RISK NON-MUSCLE INVASIVE BLADDER CANCER UNRESPONSIVE TO BACILLUS CALMETTE-GUERIN
    Kulkarini, Girish S.
    de Wit, Ronald
    Balar, Arjun V.
    Kamat, Ashish
    Uchio, Edward
    Mourey, Loic
    Krieger, Laurence
    Singer, Eric A.
    Bajorin, Dean
    Grivas, Petros
    Seo, Ho Kyung
    Nishiyama, Hiroyuku
    Konety, Badarinath
    Nam, Kijoeng
    Kapadia, Ekta
    Frenkl, Tara
    Boormans, Joost L.
    [J]. JOURNAL OF UROLOGY, 2019, 201 (04): : E616 - E616
  • [10] PEMBROLIZUMAB (PEMBRO) FOR PATIENTS (PTS) WITH HIGH-RISK NON-MUSCLE-INVASIVE BLADDER CANCER (HR NMIBC) UNRESPONSIVE TO BACILLUS CALMETTE-GUERIN (BCG): EFFICACY AND EVALUATION OF SUBSEQUENT CYSTECTOMY FROM COHORT B OF THE PHASE 2 KEYNOTE-057 STUDY
    Singer, Eric
    Necchi, Andrea
    Roumiguie, Mathieu
    Esen, Ahmet Adil
    Lebret, Thierry
    de Wit, Ronald
    Bajorin, Dean F.
    Krieger, Laurence E. M.
    Kandori, Shuya
    Uchio, Edward M.
    Seo, Ho Kyung
    Boormans, Joost
    Kamat, Ashish M.
    Grivas, Petros
    Nishiyama, Hiroyuki
    Baranwal, Pranshu
    Kapadia, Ekta
    Van den Sigtenhorst-Fijlstra, Margot
    Kulkarni, Girish S.
    Shore, Neal D.
    [J]. JOURNAL OF UROLOGY, 2023, 209 : E1195 - E1195
12345